294 related articles for article (PubMed ID: 1909452)
1. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis.
Marshall BC; Carroll KC
Semin Respir Infect; 1991 Mar; 6(1):11-8. PubMed ID: 1909452
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa.
McCormick LL; Karulin AY; Schreiber JR; Greenspan NS
J Immunol; 1997 Apr; 158(7):3474-82. PubMed ID: 9120309
[TBL] [Abstract][Full Text] [Related]
3. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
Meluleni GJ; Grout M; Evans DJ; Pier GB
J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
[TBL] [Abstract][Full Text] [Related]
4. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.
Pier GB; Saunders JM; Ames P; Edwards MS; Auerbach H; Goldfarb J; Speert DP; Hurwitch S
N Engl J Med; 1987 Sep; 317(13):793-8. PubMed ID: 2957591
[TBL] [Abstract][Full Text] [Related]
5. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
6. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
7. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
Fick RB; Sonoda F; Hornick DB
Semin Respir Infect; 1992 Sep; 7(3):168-78. PubMed ID: 1475541
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas respiratory infection in cystic fibrosis: a possible defect in opsonic IgG antibody?
Fick RB; Reynolds HY
Bull Eur Physiopathol Respir; 1983; 19(2):151-61. PubMed ID: 6871494
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary host defense: defects that lead to chronic inflammation of the airway.
Hornick DB
Clin Chest Med; 1988 Dec; 9(4):669-78. PubMed ID: 3148383
[TBL] [Abstract][Full Text] [Related]
10. Modulation of macrophage function for defence of the lung against Pseudomonas aeruginosa.
Speert DP; Wong SY; Macdonald M; Sargeant R
Behring Inst Mitt; 1997 Feb; (98):274-82. PubMed ID: 9382751
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
Savoia D; Deplano C; Zucca M
Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
[TBL] [Abstract][Full Text] [Related]
12. Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase.
Bainbridge T; Fick RB
J Lab Clin Med; 1989 Dec; 114(6):728-33. PubMed ID: 2512365
[TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G; Shand GH; Fomsgaard A; Høiby N
APMIS; 1992 Feb; 100(2):175-80. PubMed ID: 1554493
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis.
Govan JR; Harris GS
Microbiol Sci; 1986 Oct; 3(10):302-8. PubMed ID: 3155268
[TBL] [Abstract][Full Text] [Related]
15. Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay.
LeBlanc CM; Bortolussi R; Issekutz AC; Gillespie T
Clin Invest Med; 1982; 5(2-3):125-8. PubMed ID: 6811181
[TBL] [Abstract][Full Text] [Related]
16. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Pressler T
APMIS Suppl; 1996; 66():1-41. PubMed ID: 8972694
[No Abstract] [Full Text] [Related]
17. Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
Speert DP
Surv Synth Pathol Res; 1985; 4(1):14-33. PubMed ID: 3927464
[No Abstract] [Full Text] [Related]
18. Immunology of Pseudomonas aeruginosa infection in cystic fibrosis.
Høiby N; Pedersen SS; Jensen ET; Pressler T; Shand GH; Kharazmi A; Döring G
Acta Univ Carol Med (Praha); 1990; 36(1-4):16-21. PubMed ID: 2130683
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
Murray TS; Egan M; Kazmierczak BI
Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
[TBL] [Abstract][Full Text] [Related]
20. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
Moss RB
Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
